A. Acetaminophen may trigger aspirin-exacerbated asthma. B. Exercise-induced asthma represents the most costly asthma phenotype. C. Allergic asthma is characterized by the presence of low-normal IgE levels. D. Macrolide antibiotics may play a role in neutophilic asthma management.

A. Histamines B. Chemokines C. Leukotrienes D. Blood eosinophils

A. Omalizumab: anti-IL-5 B. Mepolizumab: anti-IgE C. Reslizumab: anti-IL-5 D. Lebrikuzimab: anti-IL-4

A. Anti-IgE B. Anti-IL-5 C. Anti-IL-4 receptor D. Anti-IL13

A. Recognition of the difference between daily maintenance inhaler use and use of rescue inhalers. B. Provision of standardized health education that is consistent between conflicting different healthcare providers and specialties. C. Presence of low health literacy, leading to inability to utilize inhaler devices properly. D. Provision of culturally-competent counseling on the proper use of inhaler devices, including technique.

A. Pharmacist workflow does not permit excursions from dispensing functions to focus on clinical activities. B. Patient failure to recognize the need for pharmacist intervention in optimizing their medication use. C. Lack of training or support for carrying out asthma management services. D. All of the above represent barriers to the inclusion of the pharmacist as a comprehensive asthma management team member.

A. Assessing medication compliance, including evaluating inhaler technique. B. Evaluating co-existing medical conditions that can exacerbate asthma symptoms. C. Investigating the presence of medication allergies and history of hypersensitivity reactions. D. Confirming the diagnosis of asthma, including ruling out other pulmonary causes of symptoms.

A. Access to prescription pricing data. B. Inaccessibility due to competing professional demands in the workplace. C. Extensive training in pharmacotherapy and patient counseling techniques. D. Ability to provide a written asthma action plan for all patients receiving inhaler devices.

A. Poor inhaler technique. B. Reduction in trigger exposure. C. Anti-inflammatory medication overuse. D. Presence of psychiatric comorbidities, such as depression.

A. have a four-fold increased utilization of controller medications. B. incur 2.9-fold higher adjusted asthma-related costs. C. expend 2.1-fold higher adjusted asthma medication costs. D. experience approximately equivalent rates of healthcare resource utilization.